Scholars@Duke

• Background
• 

  Education, Training, & Certifications

  • M.D., West Virginia University 2000
• 

  Duke Appointment History

  • Assistant Consulting Professor of Child & Adolescent Psychiatry in the Department of Psychiatry and Behavioral Sciences, Psychiatry, Child & Family Mental Health & Developmental Neuroscience, Psychiatry & Behavioral Sciences 2007 - 2008
• Recognition
• 

  In the News

  • MAR 30, 2015

    Macleans

    The science is in: God is the answer
• Research
• 

  Selected Grants

  • An Open-label, 52-Week, Multicenter Trial Evaluating the Long-term Safety and Tolerability of Centanafadine Sustained-Release Tablets in Adults with Attention-Deficit/Hyperactivity Disorder awarded by Otsuka America Pharmaceutical 2019 - 2021
  • A Phase 3, Randomized, Double-blind, Multicenter, Placebo-controlled, Parallel-group Trial Evaluating the Efficacy, Safety, and Tolerability of Centanafadine Sustained-release Tablets in Adults w/ADHD awarded by Otsuka American Pharmaceutical, Inc 2018 - 2021
  • Paternal Transgenerational Epigenetic Legacy from Use of Cannabis awarded by John Templeton Foundation 2017 - 2020
  • Environment Cue-Reactivity: Brain, Behavior and Clinical Outcomes in Tobacco Use awarded by National Institutes of Health 2014 - 2020
  • A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLELGROUP, ADULT LABORATORY CLASSROOM STUDY TO EVALUATE THE SAFETY AND EFFICACY OF PRC-063 COMPARED TO PLACEBO IN ADULTS WITH ADHD awarded by Purdue Pharma 2018 - 2020
  • KP415.E01: "A Multicenter, Dose-optimized, double-blind, randomized, placebo-controlled, parallel efficacy laboratory classroom study with KP415 in children with attention-deficit/hyperactivity disorder" awarded by KemPharm, Inc 2017 - 2019
  • Neurobehavioral substrates of propranolol's effects on drug cue reactivity awarded by National Institutes of Health 2017 - 2019
  • A Phase 3, Open-label, Multicenter, 12-Month Safety and Tolerability Study of SPD489 in Preschool Children Aged 4-5 Years Diagnosed with Attention-deficit/Hyperactivity Disorder awarded by Shire Pharmaceutical Development US Inc. 2015 - 2019
  • A Phase 4, 6-Month Open-Label Extension Study to Evaluate the Safety, Tolerability, and Efficacy of Quillichew (Methylphenidate Hydrochloride (HCl) Extended Release Chewable Tablets (ERCT) in Children with Attention Deficit Hyperactivity Disorder awarded by Pfizer, Inc. 2018 - 2019
  • A phase 4, double-blind, randomized, parallel group, placebo-controlled study of the efficacy and safety of Quillichew Extended Release chewable tablets (methylphenidate HCl extended release chewable tablets ERCT) in 4-5 year old chldren with ADHD awarded by Pfizer, Inc. 2018 - 2019
  • Behavioral and genetic mechanisms of smoking risk in individuals with ADHD awarded by National Institutes of Health 2012 - 2018
  • A Pharmacokinetic Study of Aptensio XR¿ (Methylphenidate Hydrochloride) Extended-Release capsules in Male or Female Pre-School Children 4 to Under 6 years of age with ADHD in Fed Condition awarded by Rhodes Pharmaceuticals L.P. 2015 - 2018
  • A Phase 2, Open-label, Multicenter, Exploratory Safety, Tolerability, Pharmacokinetic, and Efficacy Study of SPD489 in Preschool Children Aged 4-5 Years with Attention Deficit/Hyperactivity Disorder awarded by Shire Pharmaceutical Development US Inc. 2015 - 2017
  • A 6-week, Randomized, Double-blind, Multicenter, Placebo-controlled, Parallel-group Efficacy and Safety Study of Dasotraline versus Placebo in Subjects 6 to 12 Years of Age with Attention Deficit Hyperactivity Disorder (ADHD) awarded by Sunovion Pharmaceuticals, Inc 2015 - 2017
  • A Randomized, Double-blind, Multicenter, Placebo-controlled, Parallel-group, Efficacy and Safety Study of 2 Doses of Dasotraline in Adults with Attention Deficit Hyperactivity Disorder (ADHD) awarded by Sunovion Pharmaceuticals, Inc 2015 - 2017
  • A Ph. 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Study to Evaluate the Safety & Efficacy of Evening-dosed HLD200, a Novel Delayed & ER Formulation (DELEXIS) of Methylphenidate Hydrochloride, on Post waking, Early Mor awarded by Ironshore Pharmaceuticals & Development, Inc 2015 - 2016
  • An Open-label, Flexibly-dosed, 26-Week Extension Safety Study of Dasotraline in Children and Adolescents with Attention Deficit Hyperactivity Disorder (ADHD) awarded by Sunovion Pharmaceuticals, Inc 2015 - 2016
  • SEP-225289 in Adults with Attention Deficit Hyperactivity Disorder (ADHD) awarded by Sunovion Pharmaceuticals, Inc 2014 - 2016
  • A Phase IIb, Randomized, Double-Blind, Multicenter, Placebo-Controlled, Crossover, Safety and Efficacy Study of Centanafadine Sustained-Release (CTN SR) in Adults with Attention-Deficit Hyperactivity Disorder (ADHD) awarded by Neurovance 2015 - 2016
  • A Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Evaluation of Single Oral Doses of SEP-225289 in Subjects 6 to 17 Years of Age with Attention Deficit Hyperactivity Disorder awarded by Sunovion Pharmaceuticals, Inc 2015
  • A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-ARM, MULTI-CENTER STUDY MEASURING THE EFFICACY AND SAFETY OF PRC-063 IN ADOLESCENT ADHD PATIENTS awarded by Purdue Pharma L.P. 2014 - 2015
  • A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-ARM, MULTI-CENTER STUDY MEASURING THE EFFICACY AND SAFETY OF PRC-063 IN ADULT ADHD PATIENTS awarded by Purdue Pharma L.P. 2014 - 2015
  • A SIX-MONTH, OPEN-LABEL, MULTI-CENTER STUDY OF THE SAFETY AND EFFICACY OF PRC-063 IN ADULTS AND ADOLESCENTS WITH ADHD awarded by Purdue Pharma L.P. 2014 - 2015
  • A Phase III Clinical Endpoint Evaluation Study Examining the Safety and Efficacy of HLD200 in Pediatric Subjects with Attention-Deficit Hyperactivity Disorder (CEES ADHD) awarded by Ironshore Pharmaceuticals & Development, Inc 2014 - 2015
  • A 6-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MG01CI (Metadoxine Immediate-release/Slow-release, Bilayer Caplet) 1400 mg Compared with Placebo in Adults with Attention Deficit/Hyperactivity Disorder (ADHD) awarded by Alcobra Ltd. 2014 - 2015
  • Amphetamine Extended-Release Oral Suspension in the Treatment of Children with ADHD: A Laboratory School Study awarded by Tris Pharma, Inc. 2014 - 2015
  • Neuropharmacology of Response Inhibition in Comorbid ADHD and Nicotine Dependence awarded by National Institutes of Health 2009 - 2014
  • Neural Substrates of Extinction-Based Treatment for Nicotine Dependence awarded by National Institutes of Health 2008 - 2014
  • Smoking reinforcement in adults with and without ADHD awarded by National Institutes of Health 2009 - 2012
• Publications & Artistic Works
• 

  Selected Publications

  • Academic Articles

    • Dew, Rachel E., Bernard Fuemmeler, and Harold G. Koenig. “Trajectories of Religious Change From Adolescence to Adulthood, and Demographic, Environmental, and Psychiatric Correlates.” J Nerv Ment Dis 208, no. 6 (June 2020): 466–75. https://doi.org/10.1097/NMD.0000000000001154.
       Full Text  Link to Item
    • Kollins, Scott H., Erin N. Schoenfelder, Joseph S. English, Alex Holdaway, Elizabeth Van Voorhees, Benjamin R. O’Brien, Rachel Dew, and Allan K. Chrisman. “An exploratory study of the combined effects of orally administered methylphenidate and delta-9-tetrahydrocannabinol (THC) on cardiovascular function, subjective effects, and performance in healthy adults.” J Subst Abuse Treat 48, no. 1 (January 2015): 96–103. https://doi.org/10.1016/j.jsat.2014.07.014.
       Full Text  Link to Item
    • Kollins, Scott H., Joseph S. English, Nilda Itchon-Ramos, Allan K. Chrisman, Rachel Dew, Benjamin O’Brien, and F Joseph McClernon. “A pilot study of lis-dexamfetamine dimesylate (LDX/SPD489) to facilitate smoking cessation in nicotine-dependent adults with ADHD.” J Atten Disord 18, no. 2 (February 2014): 158–68. https://doi.org/10.1177/1087054712440320.
       Full Text  Link to Item
    • Kollins, Scott H., Erin Schoenfelder, Joseph S. English, F Joseph McClernon, Rachel E. Dew, and Scott D. Lane. “Methylphenidate does not influence smoking-reinforced responding or attentional performance in adult smokers with and without attention deficit hyperactivity disorder (ADHD).” Exp Clin Psychopharmacol 21, no. 5 (October 2013): 375–84. https://doi.org/10.1037/a0033851.
       Full Text  Link to Item
    • Bonelli, R., R. E. Dew, H. G. Koenig, D. H. Rosmarin, and S. Vasegh. “Religious and spiritual factors in depression: Review and integration of the research.” Depression Research and Treatment 2012 (December 1, 2012). https://doi.org/10.1155/2012/962860.
       Full Text
    • Vasegh, S., D. H. Rosmarin, H. G. Koenig, R. E. Dew, and R. M. Bonelli. “Religious and spiritual factors in depression.” Depression Research and Treatment 2012 (December 1, 2012). https://doi.org/10.1155/2012/298056.
       Full Text
    • Van Voorhees, E., F. J. McClernon, B. Fuemmeler, J. English, A. Holdaway, M. Hallyburton, R. Dew, and S. Kollins. “An examination of differences in variables maintaining smoking behavior in adult smokers with and without attention-deficit/hyperactivity disorder.” Addiction Research and Theory 20, no. 1 (February 1, 2012): 72–81. https://doi.org/10.3109/16066359.2011.564692.
       Full Text
    • Blalock, Leigh, and Rachel E. Dew. “A pilot survey of clergy regarding mental health care for children.” Depress Res Treat 2012 (2012): 742410. https://doi.org/10.1155/2012/742410.
       Full Text  Link to Item
    • Bidwell, L Cinnamon, Rachel E. Dew, and Scott H. Kollins. “Erratum: alpha-2 adrenergic receptors and attention-deficit/hyperactivity disorder.” Curr Psychiatry Rep 13, no. 1 (February 2011): 76. https://doi.org/10.1007/s11920-010-0171-1.
       Full Text  Link to Item
    • Dew, Rachel E., and Scott H. Kollins. “Lisdexamfetamine dimesylate: a new option in stimulant treatment for ADHD.” Expert Opin Pharmacother 11, no. 17 (December 2010): 2907–13. https://doi.org/10.1517/14656566.2010.531009.
       Full Text  Link to Item
    • Cinnamon Bidwell, L., Rachel E. Dew, and Scott H. Kollins. “Alpha-2 adrenergic receptors and attention-deficit/hyperactivity disorder.” Curr Psychiatry Rep 12, no. 5 (October 2010): 366–73. https://doi.org/10.1007/s11920-010-0136-4.
       Full Text  Link to Item
    • Dew, R. E., S. S. Daniel, D. B. Goldston, W. V. McCall, M. Kuchibhatla, C. Schleifer, M. F. Triplett, and H. G. Koenig. “A prospective study of religion/spirituality and depressive symptoms among adolescent psychiatric patients.” J Affect Disord 120, no. 1–3 (January 2010): 149–57. https://doi.org/10.1016/j.jad.2009.04.029.
       Full Text  Link to Item
    • Dew, Rachel E. “Why Psychiatry Is the Hardest Specialty.” American Journal of Psychiatry 166, no. 1 (January 2009): 16–17. https://doi.org/10.1176/appi.ajp.2008.08010091.
       Full Text
    • Dew, Rachel Elizabeth, Stephanie S. Daniel, Tonya D. Armstrong, David B. Goldston, Mary Frances Triplett, and Harold G. Koenig. “Religion/Spirituality and adolescent psychiatric symptoms: a review.” Child Psychiatry Hum Dev 39, no. 4 (December 2008): 381–98. https://doi.org/10.1007/s10578-007-0093-2.
       Full Text  Link to Item
    • Dew, Rachel E., Stephanie S. Daniel, David B. Goldston, and Harold G. Koenig. “Religion, spirituality, and depression in adolescent psychiatric outpatients.” J Nerv Ment Dis 196, no. 3 (March 2008): 247–51. https://doi.org/10.1097/NMD.0b013e3181663002.
       Full Text  Link to Item
    • Dougherty, Donald M., Rachel E. Dew, Charles W. Mathias, Dawn M. Marsh, Merideth A. Addicott, and Ernest S. Barratt. “Impulsive and premeditated subtypes of aggression in conduct disorder: differences in time estimation.” Aggress Behav 33, no. 6 (November 2007): 574–82. https://doi.org/10.1002/ab.20219.
       Full Text  Link to Item
    • Dew, Rachel E., Stephanie S. Daniel, and Harold G. Koenig. “A pilot study on religiousness/spirituality and ADHD.” Int J Adolesc Med Health 19, no. 4 (October 2007): 507–10. https://doi.org/10.1515/ijamh.2007.19.4.507.
       Full Text  Link to Item
    • Dew, Rachel E. “Informed consent for research in Borderline Personality Disorder.” Bmc Med Ethics 8 (May 10, 2007): 4. https://doi.org/10.1186/1472-6939-8-4.
       Full Text  Link to Item
    • Dew, Rachel Elizabeth, Stephen I. Kramer, and W Vaughn McCall. “Adequacy of antidepressant treatment by psychiatric residents: the antidepressant treatment history form as a possible assessment tool.” Acad Psychiatry 29, no. 3 (July 2005): 283–88. https://doi.org/10.1176/appi.ap.29.3.283.
       Full Text  Link to Item
    • Dew, Rachel E., Peter B. Rosenquist, and W Vaughn McCall. “Aripiprazole for agitation in a 13-year-old girl with neuroleptic malignant syndrome.” Int J Adolesc Med Health 17, no. 2 (April 2005): 187–88. https://doi.org/10.1515/ijamh.2005.17.2.187.
       Full Text  Link to Item
    • Dew, Rachel E., James N. Kimball, Peter B. Rosenquist, and W Vaughn McCall. “Seizure length and clinical outcome in electroconvulsive therapy using methohexital or thiopental.” J Ect 21, no. 1 (March 2005): 16–18. https://doi.org/10.1097/01.yct.0000154052.80893.f7.
       Full Text  Link to Item
    • Dew, Rachel E., and Doreen Hughes. “Acute dystonic reaction with moderate-dose ziprasidone.” J Clin Psychopharmacol 24, no. 5 (October 2004): 563–64. https://doi.org/10.1097/01.jcp.0000138780.55762.36.
       Full Text  Link to Item
    • Dew, Rachel, and W Vaughn McCall. “Efficiency of outpatient ECT.” J Ect 20, no. 1 (March 2004): 24–25. https://doi.org/10.1097/00124509-200403000-00006.
       Full Text  Link to Item

  • Book Sections

    • Dew, R., and H. Koenig. “Religion/spirituality and depression in old age.” In Practical Management of Affective Disorders in Older People: A Multi-Professional Approach, 242–52, 2018.

  • Conference Papers

    • Dew, Rachel E. “6.21 TRAJECTORIES OF RELIGIOUS DEVELOPMENT AND CORRELATIONS WITH MENTAL HEALTH FROM ADOLESCENCE TO ADULTHOOD.” In Journal of the American Academy of Child & Adolescent Psychiatry, 58:S277–78. Elsevier BV, 2019. https://doi.org/10.1016/j.jaac.2019.08.413.
       Full Text

Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.